Loading
Obesity / Diabetes Mellitus, Type 2 / Metabolic Diseases · Journal article
Annals of Medicine · July 10, 2026
A consensus or society position rather than new primary data.
This is a narrative review proposing a mechanistic framework linking sleep disturbances (deprivation, OSA, circadian disruption) to metabolic disease risk through dysregulated adipokine secretion (leptin, adiponectin, IL-6, ANGPTL4). The review synthesizes existing evidence to support integration of sleep assessment and interventions into metabolic disease prevention but does not present new experimental or clinical trial data.
Narrative review. Individuals with sleep disorders (sleep deprivation, obstructive sleep apnea, circadian rhythm disruption) and metabolic diseases (obesity, type 2 diabetes).
Sleep deprivation and fragmentation promote leptin dysregulation and reduce adiponectin levels OSA-driven intermittent hypoxia potently upregulates IL-6 and ANGPTL4 Sleep disturbances disrupt circadian rhythms and alter adipokine secretory profiles, contributing to insulin resistance, dyslipidemia, and chronic low-grade inflammation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should consider integrating sleep assessment and evidence-based sleep interventions (CPAP for OSA, sleep extension, circadian realignment) into standard preventive and clinical frameworks for metabolic disease management. This review supports positioning sleep quality as a modifiable determinant of metabolic health alongside nutrition and physical activity.
A mechanistic review synthesizing bidirectional relationships between sleep disorders and metabolic disease via adipokine dysregulation, offering a framework for clinical integration but presenting no new primary data or controlled evidence.
As stated by the source record.
Clinicians should consider integrating sleep assessment and evidence-based sleep interventions (CPAP for OSA, sleep extension, circadian realignment) into standard preventive and clinical frameworks for metabolic disease management. This review supports positioning sleep quality as a modifiable determinant of metabolic health alongside nutrition and physical activity.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background. Sleep disorders-including sleep deprivation, obstructive sleep apnea (OSA), and circadian rhythm disruption-and metabolic diseases such as obesity and type 2 diabetes represent major, interconnected public health challenges. This review aims to synthesize current evidence on the bidirectional crosstalk between these conditions, with a focus on the mediating role of dysregulated adipokine secretion.Discussion. We elaborate a mechanistic framework wherein specific sleep disturbances disrupt circadian rhythms and alter the secretory profiles of key adipokines, including leptin, adiponectin, interleukin-6 (IL-6), and angiopoietin-like protein 4 (ANGPTL4). Sleep deprivation and fragmentation promote a state of leptin dysregulation and reduce adiponectin levels, while OSA-driven intermittent hypoxia potently upregulates IL-6 and ANGPTL4. These alterations collectively contribute to insulin resistance, dyslipidemia, and chronic low-grade inflammation, thereby elevating metabolic disease risk. Conversely, obesity and diabetes exacerbate sleep disorders through pathways involving visceral adiposity, neuroendocrine dysfunction (e.g. HPA-axis activation), and diabetes-related symptoms (e.g. nocturia, neuropathic pain), forming a vicious cycle. Clinical and preclinical evidence underscores that the synchronization of sleep-circadian biology is fundamental to maintaining adipokine homeostasis and metabolic health.Conclusion. The evidence positions sleep and circadian health as critical, modifiable determinants of metabolic risk. Integrating sleep assessment and evidence-based interventions (e.g. CPAP for OSA, sleep extension, circadian realignment) into standard preventive and clinical frameworks for metabolic diseases is a promising strategy. Public health initiatives should elevate 'quality sleep' as a pillar of health alongside nutrition and physical activity to mitigate the intertwined epidemics of metabolic and sleep disorders.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.